{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"We evaluated the number of patients who developed a related adverse event as assessed by the CTCAE version 4.0.","groups":[{"description":"* Nivolumab will be given every two weeks\n* The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle\n\nNivolumab: Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.\n\nDC/myeloma fusions/GM-CSF: The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.","id":"OG000","title":"Nivolumab+DC/Myeloma Fusions/GM-CSF"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who developed treatment-related adverse events","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0","type":"SECONDARY","unitOfMeasure":"Participants"}